Table 1.
Clinical and laboratory characteristics of patients with systemic sclerosis (SSc) positive for anti-CD22 autoantibodies
| Anti-CD22 positive (n = 11) | Anti-CD22 negative (n = 32) | |
|---|---|---|
| Sex (female/male) | 9/2 | 26/6 |
| Clinical features | ||
| Median (range) TSS | 13 (1–39)* | 5 (1–40) |
| Pitting scar | 56 | 42 |
| Nailfold bleeding | 78 | 85 |
| Raynaud's phenomenon | 77 | 87 |
| Organ involvement | ||
| Pulmonary fibrosis | 64 | 70 |
| Decreased %VC | 36 | 13 |
| Decreased %DLco | 64 | 59 |
| Heart | 0 | 21 |
| Kidney | 11 | 0 |
| Joint | 33 | 29 |
| Oesophagus | 89 | 47 |
| Muscle | 11 | 29 |
| Laboratory data | ||
| Positive anti-topoisomerase I antibody | 55 | 35 |
| Positive anti-centromere antibody | 33 | 35 |
| Positive anti-U1RNP antibody | 0 | 5·8 |
| Elevated CRP level | 0 | 13 |
| Elevated ESR | 36 | 25 |
| IgG, median (range) mg/dl | 1420 (1199–2790) | 1385 (846–2541) |
| SP-A, median (range) ng/dl | 46·7 (19·1–56·9) | 36·8 (8·3–158) |
| SP-D, median (range) ng/dl | 137 (44–502)* | 73·2 (29·2–311) |
| KL-6, median (range) U/ml | 370 (201–1156) | 269 (138–2629) |
*
P < 0·05. Unless noted otherwise, values are percentages. TSS, modified Rodnan total skin thickness score; VC, vital capacity; Dlco, diffusing capacity for carbon monoxide; SP-A, pulmonary surfactant protein A; SP-D, pulmonary surfactant protein D; KL-6, sialyated carbohydrate antigen KL-6; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.